Hannah Dukeman, APRN
Diabetes Educator · Mattoon, ILNPI 1326415845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 277 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$740
- Novartis$472
- Lilly USA, LLC$402
- Boehringer Ingelheim$396
- Dexcom, Inc.$387
- Corcept Therapeutics$336
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,999100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $740 |
| Novartis | 31 | $472 |
| Lilly USA, LLC | 19 | $402 |
| Boehringer Ingelheim | 17 | $396 |
| Dexcom, Inc. | 16 | $387 |
| Corcept Therapeutics | 18 | $336 |
| Radius Health, Inc. | 16 | $321 |
| Bayer | 13 | $288 |
| Insulet Corporation | 13 | $284 |
| Xeris Pharmaceuticals, Inc. | 13 | $246 |
| AstraZeneca(2 entities) | 13 | $228 |
| Tandem Diabetes Care, Inc. | 11 | $202 |
| Amgen(2 entities) | 10 | $160 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| AbbVie | 3 | $78 |
| Sequel Med Tech, LLC | 3 | $62 |
| Abbott | 3 | $55 |
| Medtronic | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| BETA Bionics, Inc. | 2 | $34 |
| Recordati_rare_diseases_inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Cequr Corporation | 1 | $10 |
How this compares
Too few diabetes educator providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 429 | $447,578 |
| MounjaroTirzepatide | 299 | $320,061 |
| TrulicityDulaglutide | 188 | $191,336 |
| JardianceEmpagliflozin | 222 | $183,840 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 129 | $132,728 |
| FarxigaDapagliflozin Propanediol | 115 | $94,730 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $92,741 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 135 | $67,242 |
| RybelsusSemaglutide | 39 | $54,164 |
| Victoza 3-PakLiraglutide | 54 | $44,925 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $43,678 |
| Humulin R U-500Insulin Regular, Human | 23 | $36,519 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $35,124 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $34,631 |
| Novolog FlexpenInsulin Aspart | 173 | $34,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $740 | $542,932590 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $402 | $520,348521 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $396 | $208,227258 claims |
| AstraZenecaFarxiga | $228 | $94,730115 claims |
| Sanofi-aventis U.S. LLCAdmelog | $101 | $8,16015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few diabetes educator providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other diabetes educator in Mattoon
- Carol HammellChicago$185
- Lorraine IoccaSpringfield$176
- Luis FloresChicago$169
- Tracy WeberRockford$140
- Gail MeyersonEvanston$125
- Lianna GreeneBuffalo Grove$122
- Shelby MainChicago$115
- Mirian MendezGeneva$111
- Rosetta SheppardChicago$111
- Catherine GeraciChicago$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.